A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice

Sponsor
Novo Nordisk A/S
Study ID
NCT04094415
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.

Study Details

The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed to them by their doctor. The study will last for about 6 to 8 months. Participants will be asked to complete some questionnaires about their health and your diabetes treatment. Participants will complete these during their normally scheduled visits with their doctor.

Key Dates

Start date
Oct 28, 2019
Status verified
Feb 2023
Primary completion
Jul 28, 2021
Completion
Jul 28, 2021

Study Design

Enrollment
581 participants (actual)

Arms

  • Arm: Semaglutide
    Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.

Primary Outcome Measure

Change in Glycated Haemoglobin A1c (HbA1c) (measured in percent) [ Time Frame: Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38) ]

Related Studies